# DAPK-IN-2

MedChemExpress

HY-153595			
304000-05-3			
C <sub>17</sub> H <sub>14</sub> N <sub>2</sub> O <sub>4</sub>			
310.3			
Others			
Others			
Powder	-20°C	3 years	
	4°C	2 years	
In solvent	-80°C	6 months	
	-20°C	1 month	
	304000-05-3 C <sub>17</sub> H <sub>14</sub> N <sub>2</sub> O <sub>4</sub> 310.3 Others Others Powder	304000-05-3 $C_{17}H_{14}N_2O_4$ 310.3 Others Others Powder -20°C 4°C In solvent -80°C	

## SOLVENT & SOLUBILITY

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.2227 mL	16.1134 mL	32.2269 mL
	5 mM	0.6445 mL	3.2227 mL	6.4454 mL
	10 mM			
Please refer to the so	lubility information to select the app	propriate solvent.		

BIOLOGICAL ACTIVITY						
nfarction and ischemic diseases <sup>[1]</sup> .						
reference only.						

#### REFERENCES

[1]. Okamoto M, et al. Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening. Bioorg Med Chem. 2010;18(7):2728-2734.

# Product Data Sheet

0

O

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA